.Pharmacolibrary.Drugs.ATC.R.R03AK14

Information

Indacaterol and mometasone is a fixed-dose combination medication containing indacaterol, a long-acting beta2-adrenergic agonist (LABA), and mometasone furoate, an inhaled corticosteroid (ICS). It is used for the maintenance treatment of asthma in adults and adolescents. The combination provides bronchodilation and anti-inflammatory effects, and is approved in several countries for asthma management.

Pharmacokinetics

Pharmacokinetic parameters are estimated based on the known pharmacokinetic properties of indacaterol and mometasone furoate in healthy adults following inhalation; fixed-dose combination pharmacokinetics are assumed to be additive of the single components.

References

1. Inoue, S, et al., & Furihata, K (2021). Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects. BMC pulmonary medicine 21(1) 18–None. DOI:10.1186/s12890-020-01382-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33413291

2. Bartels, C, et al., & Vaidya, S (2021). Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler. European journal of drug metabolism and pharmacokinetics 46(4) 487–504. DOI:10.1007/s13318-021-00689-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/34024035

3. Shimada, S, et al., & Kobayashi, K (2015). Pharmacokinetics of QMF149 in Japanese versus Caucasian subjects: an open-label, randomized phase I study. International journal of clinical pharmacology and therapeutics 53(5) 398–407. DOI:10.5414/CP202239 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25740265

Revisions

• 06/2025 initial generated model